A news release from last Wednesday stated that the clinical trial of NSABP C-08 was negative.
This was the clinical trial testing whether the addition of Avastin to FOLFOX would increase efficacy in reducing recurrence for patients with stage II and III colon cancer. FOLFOX was given over 6 months compared to FOLFOX in combination with Avastin for 6 months, followed by additional 6 months of Avastin. There was a great hope that this anti-VEGF therapy would further decrease tumor recurrence. Read the rest of this entry »